VXRT - Vaxart soars after hours on $453M award to evaluate COVID-19 oral pill vaccine candidate
2024-06-13 17:16:41 ET
More on Vaxart
- Vaxart, Inc. (VXRT) Q1 2024 Earnings Call Transcript
- Vaxart up 10% on quarterly revenue beat, eyes COVID oral vaccine trial start in Q2
- Vaxart GAAP EPS of -$0.14 in-line, revenue of $2.18M beats by $1.38M
- Seeking Alpha’s Quant Rating on Vaxart
- Historical earnings data for Vaxart